One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study-MedSci.cn

One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study

Cohen, R; Meurisse, A; Pudlarz, T; Bennouna, J; Tournigand, C; De La Fouchardiere, C; Tougeron, D; Borg, C; Mazard, T; Chibaudel, B; Garcia-Larnicol, ML; Svrcek, M; Menu, Y; Vernerey, D; Andre, T

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (4):

科室
- - 订阅+
  - 更多科室
工具
服务